RAPP insider trading — Rapport Therapeutics, Inc.
No open-market insider purchases or sales were filed for Rapport Therapeutics, Inc. (RAPP) in the last 90 days. Other insider transactions — such as stock awards, option exercises or tax withholding — are listed below.
Updated Oct 16, 2026.
Recent RAPP insider transactions
Every Form 4 filed by Rapport Therapeutics, Inc. officers, directors and 10% owners in the last 90 days, newest first. P = open-market purchase, S = open-market sale; other codes are awards, option exercises, tax withholding or gifts.
| Trade date | Insider | Role | Type | Ownership | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| Oct 7, 2026 | Ceesay Abraham | Chief Executive Officer | S · Sale · 10b5-1 | Direct | 1,147 | $30.66 | $35K | Form 4 |
| Oct 6, 2026 | Ceesay Abraham | Chief Executive Officer | S · Sale · 10b5-1 | Direct | 3,375 | $32.03 | $108K | Form 4 |
| Sep 30, 2026 | Gault Cheryl | Chief Operating Officer | S · Sale · 10b5-1 | Direct | 10,000 | $33.19 | $332K | Form 4 |
| Sep 23, 2026 | Ceesay Abraham | Chief Executive Officer | S · Sale · 10b5-1 | Direct | 2,210 | $39.17 | $87K | Form 4 |
| Sep 8, 2026 | Ceesay Abraham | Chief Executive Officer | S · Sale · 10b5-1 | Direct | 8,210 | $45.61 | $374K | Form 4 |
| Aug 25, 2026 | Ceesay Abraham | Chief Executive Officer | S · Sale · 10b5-1 | Direct | 18,921 | $49.57 | $938K | Form 4 |
| Aug 25, 2026 | Yeleswaram Krishnaswamy | Chief Development Officer | S · Sale · 10b5-1 | Direct | 37,000 | $50.64 | $1.87M | Form 4 |
| Aug 24, 2026 | Yeleswaram Krishnaswamy | Chief Development Officer | S · Sale · 10b5-1 | Direct | 13,160 | $50.00 | $658K | Form 4 |
| Aug 19, 2026 | Yeleswaram Krishnaswamy | Chief Development Officer | S · Sale · 10b5-1 | Direct | 404 | $49.90 | $20K | Form 4 |
| Aug 11, 2026 | Ceesay Abraham | Chief Executive Officer | S · Sale · 10b5-1 | Direct | 28,958 | $48.01 | $1.39M | Form 4 |
| Aug 10, 2026 | Ceesay Abraham | Chief Executive Officer | S · Sale · 10b5-1 | Direct | 22,541 | $46.26 | $1.04M | Form 4 |
| Jul 27, 2026 | Ceesay Abraham | Chief Executive Officer | S · Sale · 10b5-1 | Direct | 2,210 | $42.11 | $93K | Form 4 |
RAPP insider trading FAQ
Are insiders buying RAPP stock?
Not on the open market. In the last 90 days, Rapport Therapeutics, Inc. insiders made no open-market purchases, and no open-market sales. Purchases with the insider's own money are generally seen as a stronger signal than sales, which happen for many reasons (taxes, diversification, planned 10b5-1 sales).
Who are the insiders trading RAPP?
No insider bought or sold on the open market in the last 90 days.
Where does RAPP insider trading data come from?
Every transaction comes from SEC Form 4 filings on EDGAR. Company officers, directors and 10% owners must file a Form 4 within two business days of buying or selling. InsiderBolt reads these filings directly from the SEC.
More stocks with insider activity
Insider trading data is for informational purposes only and is not investment advice. Filings can be amended; always confirm details on SEC EDGAR.